Represents the information relating to matters concerning the entity pertaining to Abbott and Laboratories Fournier SA.
Abbott and Laboratories Fournier S.A.
Abbott and Laboratories Fournier S A [Member]
Accrued Deferred Share Units Current
DSUs
Carrying value as of the balance sheet date of obligations incurred through that date and payable for deferred share units. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
ACCRUED LEGAL SETTLEMENTS
ACCRUED LEGAL SETTLEMENTS
Accrued Legal Settlements [Text Block]
Disclosure of all information related to accrued legal settlements.
Accrued Product Rebate Current
Product rebates
Represents the current portion of accrued product rebates.
Accrued Product Return Current
Product returns
Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Award Type [Axis]
Accrued Unpaid Cash Consideration Related to Merger Current
Unpaid cash consideration related to the Merger
Carrying value as of the balance sheet date of obligations incurred through that date and payable for unpaid cash consideration related to the merger. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Accumulated Losses Available for Federal Purposes
Accumulated losses available for federal and provincial purposes
Represents the details pertaining to accumulated losses available for federal and provincial purposes.
Accumulated Other Comprehensive Income Loss [Line Items]
Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) Net of Tax [Roll Forward]
Components of accumulated other comprehensive income
Amendment Description
Accumulated Other Comprehensive Income Loss [Table]
Schedule of accumulated other comprehensive income (loss).
Amendment Flag
Acquired IPR&D
Represents intangible assets that the entity has acquired as a result of business acquisition, which is represented through the premium in the purchase price over book value attributed to research and development on new product that is not yet being sold.
Acquired in Process Research and Development [Member]
Acquisition Accounting Adjustment on Inventory Sold
Acquisition accounting adjustment on inventory sold
Represents the acquisition accounting adjustment on inventory sold during the reporting period.
AUSTRALIA
Australia
ACQUISITIONS AND DISPOSITIONS
Acquisition Disclosure [Text Block]
ACQUISITIONS
Description of assets acquired and liabilities assumed during the period that either do or do not constitute a business, including background, timing, and recognized assets and liabilities. This element may be used as a single block of text to encapsulate the entire disclosure (including data and tables) regarding business combinations and asset acquisitions.
Acquisitions Dispositions Disclosures [Text Block]
ACQUISITIONS AND DISPOSITIONS
Description of net assets acquired or disposed of during the period that do not constitute a business, including background, timing, and affected assets and liabilities. This element may be used as a single block of text to encapsulate the entire disclosure (including data and tables) regarding asset acquisitions and disposals.
Adjustments to Additional Paid In Capital Conversion of Convertible Debt
Charges to additional paid-in capital for difference between estimated fair value of notes and fair value of common shares issued upon settlement
Adjustment to additional paid in capital resulting from the conversion of convertible debt.
All Countries [Domain]
Adjustments to Additional Paid in Capital, Early Repayments of Convertible Debt
Difference between the estimated fair value and the purchase price of securities charged to additional paid-in capital
Represents the difference between the fair value of payments made and the carrying amount of debt, charged to additional paid-in capital.
Arrangements and Non-arrangement Transactions [Domain]
Reclassification of deferred share units
Adjustments to Additional Paid in Capital Reclassification of Deferred Share Units
This element represents adjustment to Additional Paid in Capital resulting from the reclassification of deferred share units.
Adjustments to Common Stockholders Equity Early Repayments of Convertible Debt
Difference between the net carrying amount and the purchase price of securities charged to shareholders' equity
Represents the difference between the net carrying amount and the carrying amount of debt, charged to shareholders' equity.
Adjustments to Retained Earnings (Accumulated Deficit) Conversion of Convertible Debt
Charges to accumulated deficit for difference between estimated fair value of notes and fair value of common shares issued upon settlement
Adjustment to retained earnings (accumulated deficit) resulting from the conversion of convertible debt.
All Exchanges [Domain]
Afexa Life Sciences Inc [Member]
Afexa
Represents information pertaining to Afexa Life Sciences Inc. ("Afexa")
Affiliates of G S K [Member]
Affiliates of GSK
Represents the major customer of the entity, Affiliates of GSK.
Affiliates of Ortho Mc Neil Inc [Member]
Affiliates of Ortho-McNeil, Inc.
Represents the major customer of the entity, Affiliates of Ortho-McNeil, Inc.
Affiliates of Teva Pharmaceuticals Industries Ltd [Member]
Affiliates of Teva Pharmaceuticals Industries Ltd.
Represents the major customer of the entity, Affiliates of Teva Pharmaceuticals Industries Ltd.
Aggregate Principal Debt Repurchased
Represents the aggregate principal amount of debt repurchased under the securities repurchase program.
Aggregate principal amount of the 5.375% Convertible Notes repurchased
Aggregate Shares Repurchased
Represents the aggregate shares of stock repurchased under the securities repurchase program.
Aggregate common shares repurchased in connection with the securities repurchase program (in shares)
Current Fiscal Year End Date
Aggregate Shares Repurchased Consideration
Represents the aggregate consideration on shares of stock repurchased under the securities repurchase program.
Aggregate consideration on Company's common shares repurchased in connection with the Securities Repurchase Program
All Countries [Axis]
Represents information regarding countries.
All Exchanges [Axis]
Represents the information pertaining to various exchanges.
Allowances for losses on accounts receivable and inventories
Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.
Allowances for Losses on Accounts Receivable and Inventories
BRAZIL
Brazil
Alternate Types of Weighted Average Common Shares Outstanding Calculations [Axis]
Alternate Types of Weighted Average Common Shares Outstanding Calculations [Domain]
Amerisource Bergen Corporation [Member]
AmerisourceBergen Corporation
Represents the major customer of the entity, AmerisourceBergen Corporation.
Amortization expense related to intangible assets recorded as follows:
Amortization of Intangible Assets [Abstract]
Amortization of intangible assets
Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.
Amortization expense
Amortization of Intangible Assets Excluding Amortization Allocated to Revenues Cost of Good Sold
Amortization of Intangible Assets, Included in Alliance and Royalty Revenue
Alliance and royalty revenue
Aggregate amount of intangible asset amortization expense included in alliance and royalty revenue during the period.
Amount of Foreign Currency Used to Finance Business Acquisition
Remaining foreign currency consideration used to finance transaction of business combination
Represents the aggregate amount of foreign currency purchased to finance business acquisition.
Document Period End Date
CANADA
Canada
Ampakine [Member]
AMPAKINE
Represents the acquisition of certain compounds, including associated intellectual property for use in the field of respiratory depression, a brain mediated breathing disorder. The acquisition was accounted for as a purchase of IPR&D assets with no alternative future use.
Ampakin
Antidilutive Calculation [Member]
Antidilutive Calculation
Earnings per share calculation
Antidilutive Weighted Average Common Shares Outstanding [Line Items]
Antidilutive weighted average common shares outstanding [Table]
Represents the information pertaining to antitrust complaint against the entity.
Antitrust
Antitrust Complaint [Member]
Switzerland
SWITZERLAND
Represents the information relating to matter concerning the entity pertaining to Aplenzin products.
Aplenzin
Aplenzin [Member]
Represents the allegation proceeding filed by the entity, Apotex Inc.
Apotex Inc.
Apotex Inc [Member]
Asset Impairment Charges Due to Restructuring Activities
Impairment charges
Represents the charge against earnings from the aggregate write down of all assets from their carrying value to their value as a result of restructuring activities.
Asset Related to A002 Program [Member]
Represents the information pertaining to the IPR&D asset related to A002 program.
Asset related to A002 program
Entity [Domain]
Represents the information relating to matters concerning the entity pertaining to AstraZeneca Pharmaceuticals LP.
AstraZeneca Pharmaceuticals LP
Astra Zeneca Pharmaceuticals L P [Member]
Atlantis Pharma [Member]
Represents the information pertaining to the entity Atlantis Pharma.
Atlantis
Aton Pharma, Inc. ("Aton")
Represents the information pertaining to acquisition of Aton Pharma, Inc by Valeant.
Aton Pharma Inc. [Member]
Auction Market Preferred Securities Fair Value
Fair value of investment in auction rate securities
Represents the aggregate fair value of investments in auction rate securities as of the balance sheet date.
Number of shares of common stock acquired
Number of shares of available-for-sale equity securities acquired during the period.
Available For Sale, Equity Securities, Number of Shares Acquired
Available For Sale, Equity Securities Percentage of Voting Interests Acquired
Percentage of outstanding common stock acquired
Percentage of voting equity interests acquired in the purchase of equity securities classified as available-for-sale.
B C Pharma [Member]
Represents information pertaining to BC Pharma B.V. ("BC Pharma").
BC Pharma B.V. ("BC Pharma")
B M S Collaboration and Option Agreements [Member]
BMS Collaboration and Option Agreements
Represents information pertaining to the entity's collaboration and option agreements with Bristol-Myers Squibb Company (Bristol-Myers).
B V F 018 [Member]
BVF-018
Represents BVF-018, a modified-release formulation of tetrabenazine under development initially for the treatment of Tourette's Syndrome.
Biovail Corporation [Member]
Biovail
Represents the legal entity used to conduct legal activity or hold assets.
Biovail, Elan and Teva [Member]
Biovail, Elan and Teva
Represents the details pertaining to Biovail, Elan Corporation plc (Elan) and Teva Pharmaceuticals Industries Ltd. (Teva) which are jointly liable parties in litigation.
Biovail Employee Pre Merger [Member]
Biovail Employees - Pre Merger
Related to Biovail Corporation employees prior to the merger with Valeant Pharmaceuticals International.
Represents the former subsidiary of the reporting entity.
Biovail Pharmaceuticals, Inc.
Biovail Pharmaceuticals Inc [Member]
Branded Generics - Europe
Represents the Branded Generics - Europe business segment. The segment consists of branded generic pharmaceutical products sold primarily in Poland, Serbia, Hungary, the Czech Republic and Slovakia.
Branded Generics, Europe [Member]
Branded Generics - Latin America
Represents the Branded Generics - Latin America business segment. The segment consists of branded generic pharmaceutical and OTC products sold primarily in Mexico, Brazil and exports out of Mexico to other Latin American markets.
Branded Generics, Latin America [Member]
Available-for-sale Securities, Gross Unrealized Gains
Gross Unrealized Gains
Brazil Uncommitted Line of Credit [Member]
Represents the Brazil Uncommitted Line of Credit.
Brazil Uncommitted Line of Credit
Available-for-sale Securities, Debt Maturities, Date
Maximum maturity period of all marketable securities
Bupropion Hydrobromide Tablets [Member]
Bupropion Hydrobromide Tablets
Represents the information relating to matters concerning the entity pertaining to bupropion hydrobromide tablets products.
Represents the information relating to matters concerning the entity pertaining to bupropion hydrochloride tablets products.
Bupropion Hydrochloride Tablets [Member]
Bupropion Hydrochloride Tablets
Business Acquisition, Accounting Adjustments Impact on Segment Profit (Loss)
Represents the impact of acquisition accounting adjustments including, but not limited to, fair value adjustments of inventory and identifiable intangible assets, during the period.
Segment profit (loss) impact of acquisition
Business Acquisition Additional Common Shares Acquired
Additional outstanding common shares acquired
Represents the additional number of common shares acquired.
Business Acquisition, Adjunctive Treatment with Epilepsy Minimum Age Limit
Minimum age limit for adjunctive treatment with epilepsy
Represents the minimum age limit granted for market authorization as an adjunctive treatment of partial onset seizures, with or without secondary generalization in adults with epilepsy.
Business Acquisition Common Shares Acquired
Outstanding common shares acquired
Represents the aggregate number of common shares acquired.
Business Acquisition, Contingent Consideration Fair Value Disclosure
Acquisition-related contingent consideration
Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.
Business Acquisition Cost of Acquired Entity Additional Cash Paid
Additional cash consideration paid
Additional amount of cash paid to acquire the entity.
Business Acquisition Cost of Acquired Entity Additional Payments on First Anniversary
Additional cash payments on first anniversary
Amount of cash paid on to the acquiree on the first anniversary of a business acquisition.
Business Acquisition Cost of Acquired Entity Additional Payments on Second Anniversary
Additional cash payments on second anniversary
Amount of cash paid on to the acquiree on the second anniversary of a business acquisition.
Business Acquisition Cost of Acquired Entity Call Option Agreement Number of Call Options
Call option agreement, Number of call options purchased
Represents the number of call options to be purchased or written under call option agreement for shares underlying conversion of convertible notes, in a business acquisition.
Business Acquisition Cost of Acquired Entity Deferred Compensation Arrangement with Individual Post Merger Compensation Expense
Portion attributable to Mr. Pearson's post-Merger service recognized as share-based compensation expense
The cash paid to an individual under an award plan representing the portion attributable to post-merger service recognized as share-based compensation expense over the remaining vesting period.
Business Acquisition Cost of Acquired Entity Deferred Compensation Arrangement with Individual Pre Merger Compensation Expense
Portion attributable to Mr. Pearson's pre-Merger service recognized in fair value of consideration transferred
The cash paid to an individual under an award plan representing the portion attributable to pre-merger service recognized in the fair value of consideration transferred.
Business Acquisition Cost of Acquired Entity Liabilities Incurred, Contingent Consideration at Fair Value
Acquisition of businesses, contingent consideration at fair value
Represents contingent consideration at fair value of business acquisitions
Business Acquisition Cost of Acquired Entity Shares Issuable for Share Based Payment Awards Vested
Number of common shares of Biovail expected to be issued pursuant to vested share-based based awards as a result of the Merger
Number of shares expected to be issued pursuant to vested share-based based awards as a result of the merger.
Business Acquisition Fair Value of Consideration Transferred [Table Text Block]
Fair Value of Consideration Transferred
Tabular disclosure of fair value consideration transferred to acquiree to effect business acquisition.
Business Acquisition Out of Pocket Expenses Required to be Paid to Acquirer
Out-of-pocket expenses to be paid to the acquirer
Represents the out-of-pocket expenses actually incurred by the acquirer, which are to be reimbursed by the acquiree as per the merger agreement.
Percentage of additional voting equity interests acquired in the business combination.
Business Acquisition Percentage of Additional Voting Interests Acquired
Additional outstanding common shares acquired, percentage
Business Acquisition, Post Merger Special Dividend
Post-merger special dividend (in dollars per share)
Represents the post-Merger special dividend per share declared.
Business Acquisition, Pro Forma Acquisition Accounting Adjustment of Inventory Sold
Pro forma acquisition accounting adjustment on inventory sold subsequent to acquisition date
Represents the pro forma acquisition accounting adjustment on inventory that was sold subsequent to the acquisition date for a period as if the business combination or combinations had been completed at the beginning of the period.
Business Acquisition Pro Forma Acquisition Accounting Adjustment of Inventory Sold Eliminated
Elimination of Pro forma acquisition accounting adjustment on inventory sold subsequent to acquisition date
Represents the elimination of pro forma acquisition accounting adjustment on inventory that was sold subsequent to the acquisition date for a period as if the business combination or combinations had been completed at the beginning of the period.
Business Acquisition, Pro Forma Acquisition Related Costs
Pro forma acquisition-related costs
Represents the pro forma acquisition-related costs for a period as if the business combination or combinations had been completed at the beginning of the period.
Business Acquisition Pro Forma Earnings Per Share Basic and Diluted
Basic and diluted earnings (loss) per share
The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.
Business Acquisition, Purchase Price Additional Minimum Royalty to be Paid
Represents the amount of additional minimum royalty to be paid by the entity in connection with business acquisition.
Amount of additional minimum royalty to be paid
Business Acquisition, Purchase Price Allocation, Assets Acquired [Abstract]
Assets acquired
Intangible assets:
Business Acquisition Purchase Price Allocation Assets Acquired Intangible Assets [Abstract]
Greece
GREECE
Call option agreements
The amount of acquisition cost of a business combination allocated to call option agreements of the acquired entity.
Business Acquisition, Purchase Price, Allocation Call Option Agreement Amount
Business Acquisition, Purchase Price Allocation, Current Assets, Inventory Adjustment
Acquisition accounting adjustment on the Valeant inventories that were sold
Represents acquisition accounting adjustments on inventories sold during the period.
SIGNIFICANT ACCOUNTING POLICIES
Business Acquisition Purchase Price Allocation Deferred Income Taxes Asset Current
Deferred income tax assets, current
Amount of current deferred tax assets for the differences between the values assigned and the tax bases of assets and liabilities in a business combination.
Business Acquisition Purchase Price Allocation Deferred Income Taxes Asset Noncurrent
Deferred income tax assets, noncurrent
Amount of noncurrent deferred tax assets for the differences between the values assigned and the tax bases of assets and liabilities in a business combination.
Entity Well-known Seasoned Issuer
Business Acquisition Purchase Price Allocation Deferred Income Taxes Liability Current
Deferred income tax liabilities, current
Amount of current deferred tax liabilities for the differences between the values assigned and the tax bases of assets and liabilities in a business combination.
Entity Voluntary Filers
Business Acquisition Purchase Price Allocation Deferred Income Taxes Liability Noncurrent
Deferred income tax liabilities, noncurrent
Amount of noncurrent deferred tax liabilities for the differences between the values assigned and the tax bases of assets and liabilities in a business combination.
Entity Current Reporting Status
Business Acquisition Purchase Price Allocation Equity Component Convertible, Debt
Equity component of convertible debt
The amount of acquisition cost of a business combination allocated to the carrying amount of the equity component of convertible debt of the acquired entity.
Entity Filer Category
Business Acquisition Purchase Price Allocation Liability for Uncertain Tax Position
The amount of acquisition cost of a business combination allocated to the liability for uncertain tax position.
Liability for uncertain tax position
Entity Public Float
Loans payable
Business Acquisition Purchase Price Allocation Loans Payable
The amount of acquisition cost of a business combination allocated to loans payable of the acquired entity.
Entity Registrant Name
The amount of acquisition cost of a business combination allocated to the working capital adjustment.
Working capital adjustment
Business Acquisition Purchase Price Allocation Working Capital Adjustment
Entity Central Index Key
Business Acquisition, Purchase Price Milestone to be Paid
Series of potential milestones to be paid
Represents the milestone to be paid by the entity in connection with business acquisition.
Potential future milestone payments
Maximum contingent payment
Business Acquisition, Purchase Price Minimum Royalty to be Paid
Amount of minimum royalty to be paid
Represents the amount of minimum royalty to be paid by the entity in connection with business acquisition.
Business Acquisition, Purchase Price Royalty to be Paid
Series of potential royalties to be paid
Represents the royalties to be paid by the entity in connection with business acquisition.
Upfront payment
Business Acquisition, Purchase Price Upfront Payment
Represents the upfront payment made for business acquisition.
Entity Common Stock, Shares Outstanding
Business Acquisition, Restructuring and Integration Costs
This element represents the restructuring and integration costs incurred by the reporting entity in connection with the business acquisition.
Acquisition-related integration and restructuring costs
Business Acquisition Risk Adjusted Discount Rate
Risk-adjusted discount rate
The risk-adjusted discount rate used for calculating present value of projected cash flows.
Represents the risk-adjusted discount rate used to present value the projected cash flows.
Business Acquisition Stock Issuable on Vesting of Share Based Compensation Value
Fair value of common shares to be issued pursuant to vested Valeant RSUs
Value of stock to be issued on vesting of share-based awards, pursuant to acquisitions during the period.
Business Acquisition Termination Fee Required to be Paid to Acquirer
Termination fee required to be paid to the acquirer
Represents the termination fee that is required to be paid by the acquiree to the acquirer as per the merger agreement.
Business Acquisition, Upfront and Contingent Consideration at Fair Value
Fair value of upfront and contingent consideration
Fair value, as of the acquisition date, of upfront and contingent consideration payments on business acquisition.
Business Combination, Acquired Receivables Royalty and Other Receivables Fair Value
Fair value of royalty and other receivable acquired
Represents the fair value of royalty and other receivables acquired business combination.
Business Combination, Acquired Receivables Trade Receivables Fair Value
Fair value of trade accounts receivable acquired
Represents the fair value of the trade receivables acquired business combination.
Business Combination, Contingent Consideration Arrangements Change in Amount of Contingent Consideration Asset Cash
This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.
Acquisition-related contingent consideration
Accounts and Other Receivables, Net, Current
Other
Business Combination, Debt Issuance Costs Incurred Fair Value
Debt issuance costs incurred, fair value in the acquisition
Represents the fair value ascribed to debt issuance costs incurred in the acquisition.
Business Combination Gain (Loss) Reclassified to Earnings
Represents the amount of gains or losses in the business combination reclassified in the period to earnings from other comprehensive income.
Unrealized loss reclassified from other comprehensive income to earnings
Business Combination, Percentage of Profit Sharing, Maximum
GSK milestone payment, maximum percentage of net profits shared on sales of product
Represents the maximum percentage of net profit shared on sales of the product.
Business Combination, Percentage of Royalty Rate Payments for Product Based on Backup Compounds, Maximum
GSK milestone payment, maximum percentage of royalty on net sales of backup compounds
Represents the maximum percentage of royalty payments associated with net commercial sales of products based on backup compounds.
GSK milestone payment, maximum percentage of royalty on net sales of product outside of the Collaboration Territory
Represents the maximum percentage of royalty payments associated with net commercial sales of the product outside of the Collaboration Territory.
Business Combination, Percentage of Royalty Rate Payments Maximum Outside of the Collaboration Territory
Business Combination, Pro Forma Information Earnings or Loss of Acquiree Since Acquisition Date Actual Acquisition Accounting Adjustments
Effects of the acquisition accounting adjustments
Represents the effects of acquisition accounting adjustments included in the earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.
Business Combination, Provisional Fair Value, Adjustment Depreciation on Intangible Assets
Impact of adjustments related to provisional fair value adjustment to identifiable intangible assets
Represents the amount of adjustment to depreciation relating to provisional fair value adjustment to identifiable intangible assets acquired during the period.
Business Combination, Provisional Information Initial Accounting Incomplete Adjustment Inventory and Intangibles
This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to inventory and identifiable intangible assets acquired in connection with a business combination for which the initial accounting was incomplete.
Acquisition accounting adjustment, fair value adjustment to inventory and identifiable intangible assets
Call Option Written Cash Settlement Portion of Fair Value Reclassified as Liability
Written call options settled for cash, fair value reclassified as liability
Represents the portion of fair value of call options that were for cash during the period, which was reclassified as liability as of the reporting date.
Document Fiscal Year Focus
Number of business days in which written call options were settled
Represents the number of business days after the expiration of call options over which the written call options were settled.
Call Option Written Settlement Period
Document Fiscal Period Focus
Cambridge Obligation
Represents the payments made to Cambridge in connection with acquisition of the worldwide development and commercialization rights to tetrabenazine.
Cambridge Obligation [Member]
Canada and Australia [Member]
Canada and Australia
Represents the Canada and Australia business segment. This segment consists of pharmaceutical and OTC products sold in Canada, Australia and New Zealand.
Represents the capital expenditures, depreciation and amortization by segment.
Capital Expenditure and Depreciation and Amortization [Abstract]
Capital Expenditures, and Depreciation and Amortization
Capitalized Asset Acquisition Carrying Amount
Represents the carrying amount of the related acquired asset capitalized in connection with the acquisition.
Carrying amount
Cardinal Health, Inc.
Represents the major customer of the entity, Cardinal Health, Inc.
Cardinal Health Inc [Member]
Cary
Cary Pharmaceuticals Inc [Member]
Represents the information relating to matters concerning the entity pertaining to Cary Pharmaceuticals Inc.
Certain Other Businesses Including Canadian Rights [Member]
Certain other businesses, including Canadian rights
Represents information pertaining to certain other businesses, including Canadian rights to ACZONE, DELATESTRYL, and VIROPTIC.
Clindamycin and Benzoyl Peroxide Gel and Fluorouracil Cream [Member]
Clindamycin and benzoyl peroxide gel ("IDP-111") and Fluorouracil cream ("5-FU")
Clindamycin and Benzoyl Peroxide Gel [Member]
Clindamycin and benzoyl peroxide gel ("IDP-111")
Represents the divestitures of clindamycin and benzoyl peroxide gel (IDP-111).
Cloderm Cream
Represents the out-licensing of product rights to Cloderm Cream, 0.1% in the U.S. The product rights are recorded as intangible assets.
Cloderm [Member]
Collaboration Agreement Consideration Paid
Consideration paid for rights
Represents the amount of consideration paid for the rights under the collaboration and option agreements.
Legal Entity [Axis]
COLLABORATION AGREEMENT
Document Type
COLLABORATION AGREEMENT
Collaboration Agreement Disclosure [Text Block]
Disclosure in respect of collaboration agreement entered into by the reporting entity to develop and commercialize a new pharmaceutical product.
Collaboration Agreement Term of Rights
Term of rights
Represents the term of rights under the collaboration and option agreements.
Collaborative Agreement Milestone Payment
Milestone payment made
Represents the milestone payment made by the entity.
Collaborative Agreement Milestone Payment Received
Milestone payments received from GSK
Represents the amounts received by the reporting entity, which are based upon the achievement of specific development, regulatory or commercial milestones, in connection with the Collaboration Agreement.
Accounts Receivable, Net, Current
Trade, net
Net trade receivable
Collaborative Agreement Milestone Payment to be Received Contingent upon First Sale
Represents the milestone payment to be received contingent upon the first sale of a product under a collaborative agreement.
GSK milestone payment
Collaborative Agreement Milestone Payments Due
Milestone payments in terms of Collaboration Agreement
Represents the amounts required to be paid by the reporting entity, which are contingent upon the achievement of specific development, regulatory or commercial milestones, in connection with the Collaboration Agreement.
Milestone payments in terms of collaboration and license agreements
Collaborative Agreement Product Based on Backup Compounds Milestone Payments Due
Milestone payments in terms of Collaboration Agreement for products based on backup compounds
Represents the amounts required to be paid by the reporting entity, which are contingent upon the achievement of specific development, regulatory or commercial milestones, for products based on backup compounds, in connection with the Collaboration Agreement.
Comprehensive Income [Policy Text Block]
Comprehensive Income
Disclosure of accounting policy for comprehensive income.
Concentration of Credit Risk [Abstract]
Concentrations of Credit Risk
Concentration of Credit Risk [Policy Text Block]
Concentrations of Credit Risk
Represents the policy related to credit risk concentration.
Represents the potential payments under the contingent consideration arrangement including cash and shares.
Acquisition-related contingent consideration
Contingent Consideration Arrangement [Member]
Contingent Convertible Senior Notes 1.5 Percent Due 2032 [Member]
1.5% Contingent Convertible Senior Notes due in 2033
Represents contingent convertible senior notes with an interest rate of 1.5 percent, due in 2033.
Accounts Receivable, Gross, Current
Trade
Contingent Convertible Senior Notes 2.5 Percent Due 2032 [Member]
2.5% Contingent Convertible Senior Notes due in 2032
Represents contingent convertible senior notes with an interest rate of 2.5 percent, due in 2032.
Contingent Milestone Obligations Amount Terminated
Contingent Milestone Obligations Terminated
Represents the amount of previously disclosed payments that could have been required to be made to the counterparty under each agreement. As a result of termination of these arrangements the company has no ongoing or future obligation in respect of milestone or royalty payments.
Contract Termination, Facility Closure and Other Costs
Represents the information pertaining to contract termination, facility closure cost which includes costs to consolidate or close facilities and relocate employees, asset impairment charges to write down property, plant and equipment to fair value associated with exit from or disposal of business activities or restructurings pursuant to a plan.
Contract Termination Facility Closure and Other Costs [Member]
Conversion of Stock, Shares Conversion Ratio
Right to receive converted common shares ratio
The conversion ratio of shares converted in a noncash (or part noncash) transaction.
Convertible Debt Purchase Price
The purchase price of convertible debt.
Aggregate purchase price of convertible notes
Convertible Notes, Conversion Obligation Common Stock as Percentage of Conversion Price
Percentage of the closing sales price of the entity's common stock that the conversion price must exceed in order for the notes to be convertible
Represents the closing price of the entity's common shares during any calendar quarter as a percentage of conversion price, beyond which the notes are held as convertible.
Number of trading days before maturity date during which notes are convertible
Represents the number of days prior to maturity date during which convertible Notes are convertible at any time prior to the maturity.
Convertible Notes, Conversion Obligation Period of Consecutive Trading Days before Maturity
4.00% Convertible Notes due in November, 2013
Represents convertible notes with an interest rate of 4.00 percent, due November, 2013.
Convertible Notes Payable 4.00 Percent Due November 2013 [Member]
5.375% Convertible Notes due in August, 2014
Represents convertible notes with an interest rate of 5.375 percent, due August, 2014.
Convertible Notes Payable 5.375 Percent Due August 2014 [Member]
Convertible Senior Notes 1.375 Percent Due 2017 [Member]
1.375% Convertible Senior Notes due in 2017
Represents convertible senior notes with an interest rate of 1.375 percent, due in 2017.
Corporate brands
Represents the rights to non-patented corporate brands.
Corporate Brands [Member]
Represents the information pertaining to the corporate integrity agreement entered into by the entity with the Office of the Inspector General and the Department of Health and Human Services.
Corporate Integrity Agreement
Corporate Integrity Agreement [Member]
Corporate Operations [Member]
Corporate
Represents the corporate operations.
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]
ACCRUED LIABILITIES
Debt Conversion, Market Rate of Interest for Similar Debt
Market rate of interest on debt (as a percent)
Represents the market rate of interest of debt similar to convertible debt instrument of the reporting entity, used for arriving at the fair value of the convertible debt.
Debt Conversion, Period for Accretion of Liability Component to Face Value
Period over which value allocated to liability component is being accreted to the face value
Represents the number of years in which value allocated to the liability component is being accreted to the face value using effective interest method.
Debt Instrument, Convertible Number of Equity Instruments Consisting Purchased Call Options
Convertible notes, number of shares convertible into equity consisting of purchased call options
The number of equity instruments, that the holder of the debt instrument would receive, if the debt was converted to equity, such equity instruments consist the features of purchased call options.
Accounts Payable, Current
Accounts payable
The number of equity instruments that the holder of the debt instrument received after the debt is converted to equity, such equity instruments consist the features of purchased call options.
Debt Instrument Convertible Number of Equity Instruments Consisting Purchased Call Options Converted
Convertible notes, number of shares converted into equity consisting of purchased call options (in shares)
MEXICO
Mexico
Convertible notes, number of shares convertible into equity consisting of written call options
The number of equity instruments, that the holder of the debt instrument would receive, if the debt was converted to equity, such equity instruments consist the features of written call options.
Debt Instrument Convertible Number of Equity Instruments Consisting Written Call Options
Debt Instrument, Covenant Interest Coverage Ratio, Denominator
Interest coverage ratio to be maintained, denominator
Represents the Denominator of interest coverage ratio to be maintained, as stated in the Credit Agreement.
Debt Instrument, Covenant Interest Coverage Ratio, Numerator
Interest coverage ratio to be maintained, numerator
Represents the numerator of interest coverage ratio to be maintained, as stated in the Credit Agreement.
Debt Instrument, Covenant Leverage Ratio Incurrence of Additional Debt Lower Level Multiplier
Required lower level multiplier for leverage ratio in case of incurrence of additional debt
Represents the multiplier used to calculate minimum reduction in leverage ratio before incurrence of additional debt as compared to leverage ratio after giving effect of incurrence of debt, for applicable period on performa basis.
Represents the denominator for the maximum leverage ratio required to be maintained as of the last day of each fiscal quarter under the financial covenants.
Debt Instrument Covenant Leverage Ratio Maximum Denominator
Denominator for leverage ratio, maximum
Debt Instrument Covenant Leverage Ratio Maximum Numerator
Numerator for leverage ratio, maximum
Represents the numerator for the maximum leverage ratio required to be maintained as of the last day of each fiscal quarter under the financial covenants.
Debt Instrument, Imputed Interest Rate
Imputed Interest Rates for discounting (as a percent)
Represents the imputed interest rate used to calculate the discounted value of payments to be made.
Interbank Deposit Certificate Rate
Debt Instrument Interbank Deposit Certificate Rate [Member]
Represents the Interbank Deposit Certificate Rate used to calculate the variable rate of the debt instrument.
Debt Instrument, Interest Rate Minimum Percentage of Nations Thirty Largest Banks
Nation's thirty largest banks, minimum percentage
Represents the minimum percentage of the nations thirty largest banks which posted corporate loans.
Accounts Receivable [Member]
Trade receivables
Debt Instrument, Interest Rate Spread over Federal Funds, Effective Rate
Spread over federal funds effective rate (as a percent)
Represents the spread over the federal funds effective rate.
Debt Instrument, Issue Price as Percent of Face Value
Issue price as a percentage of par value (as a percent)
Represents the price of the debt issued as a percentage of its par value.
Debt Instrument Lenders Commitment Amount
Lenders' commitment
Represents the amount of lenders' commitment as per the commitment letter.
Debt Instrument Maturity Period
Maturity period
Represents the maturity period of the debt instrument.
Represents the length of time from the beginning of the debt instrument until the scheduled repayment.
Term of credit facility
Debt Instrument, Maturity Term
Debt Instrument, Maximum Redemption Percentage with Equity Offering Proceeds
Represents the maximum percentage of the original principal amount of the debt instrument that the entity may redeem with the net cash proceeds of qualified equity offerings.
Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings
Principal amount of notes used for conversion rate
The principal amount of convertible notes used as the denominator of the conversion ratio, which is used in determining the number of shares of the equity security into which the debt will be converted.
Debt Instrument, Principal Amount Denominator for Conversion into Common Stock
Debt Instrument Quarterly Amortization Percentage Annual Rate
Quarterly amortization of term loan facility, annual rate (as a percent)
Represents the annual rate for the amortization in quarterly installments of original principal amount of term loan facility.
Debt Instrument, Redemption Price as Percentage of Principal Amount
Represents the price at which the entity may redeem all or a portion of the debt, as a percentage of the principal amount.
Redemption price as a percentage of principal amount as per the merger agreement
Redemption price as a percentage of the principal amount
Debt Instrument Redemption Price as Percentage of Principal Amount Required by Holders Upon Change in Control
Redemption price as a percentage of principal amount required by holders upon change in control
Represents the redemption price of the debt instrument as a percentage of the principal amount as required by holders upon change in control.
Represents the price at which the entity may redeem a portion of the debt with the proceeds from a qualified equity offering, as a percentage of the principal amount.
Redemption price, using proceeds from certain equity offerings, as a percentage of the principal amount
Debt Instrument, Redemption Price as Percentage of Principal Amount with Equity Offering Proceeds
Debt Instrument, Repurchase Price Due to Change in Control as Percentage of Principal Amount
Represents the price at which the entity may be required to repurchase the debt, as a percentage of the principal amount, if the entity undergoes a change in control.
Repurchase price, as a percentage of the principal amount, change of control
The alternative reference rates that may be used to calculate the variable interest rate of the debt instrument.
Debt Instrument, Variable Rate Base [Axis]
POLAND
Poland
Warsaw, Poland
Identification of the reference rate that is used to calculate the variable interest rate of the debt instrument.
Debt Instrument, Variable Rate Base [Domain]
LIBOR
The London Interbank Offered Rate (LIBOR) used to calculate the variable interest rate of the debt instrument.
Debt Instrument Variable Rate Base, L I B O R [Member]
Base rate
Represents the base rate used to calculate the variable rate of the debt instrument.
Debt Instrument Variable Rate Base [Member]
One-month adjusted LIBOR rate
The one-month adjusted London Interbank Offered Rate (LIBOR) used to calculate the variable interest rate of the debt instrument.
Debt Instrument Variable Rate Base, One Month Adjusted L I B O R [Member]
Federal funds rate
The federal funds rate used to calculate the variable interest rate of the debt instrument.
Debt Instrument Variable Rate, Federal Funds [Member]
Debt Instrument Variable Rate Floor
Variable rate floor
Represents the variable rate floor applicable as per the debt agreement.
Debt Instrument Variable Rate L I B O R [Member]
LIBO
Represents the LIBO rate.
Debt Instrument Variable Rate, Minimum
Represents the minimum variable rate as per the credit agreement.
Minimum LIBO rate (as a percent)
Debt Issuance Costs, Incurred
Debt issuance costs incurred
Represents debt issuance costs incurred.
Transfer from restricted cash
Decrease in Restricted Cash
The value of cash inflow associated with funds that were not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.
Deferred Compensation Arrangement with Individual Pre Merger Special Dividend Cash Paid
Aggregate cash paid in payment of pre-merger special dividend
Amount of special dividend paid to the individual prior to merger.
Deferred Income Tax Noncash Expense (Benefit)
Deferred income taxes
The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.
Deferred share units (DSUs) as awarded by the entity as a form of compensation.
Deferred Share Units ("DSU")
Deferred Share Unit D S U [Member]
SERBIA
Serbia
Represents the deferred tax assets on deferred financing and share issue costs incurred by the entity.
Deferred Tax Assets, Deferred Expense Deferred Financing and Share Issue Costs
Deferred financing and share issue costs
Deferred Tax Assets, Plant, Equipment and Technology
Plant, equipment and technology
The tax effect as of the balance sheet date of the amount of the estimated future tax deductions attributable to plant, equipment and technology related items which can only be realized if sufficient taxable income is generated in future periods to enable the deduction to be taken.
Deferred Tax Assets, Scientific Research and Experimental Development Pool
Scientific Research and Experimental Development pool
Represents the deferred tax assets on scientific research and experimental development pool, of the entity.
Deferred Tax Assets, Tax Credit Carryforwards Research and Development
Research and development tax credits
The tax effect as of the balance sheet date of the amount of future tax deductions arising from unused research and development tax credit carryforwards; a tax credit carryforward is the amount by which tax credits available for utilization exceed statutory limitations for inclusion in historical filings, and which can only be utilized if sufficient tax-basis income is generated in future periods and providing tax laws continue to allow such utilization.
Deferred Tax Assets, Tax Loss Carryforwards
Tax loss carryforwards
Represents the deferred tax assets on tax loss carryforwards available to the entity.
Deferred Tax Liabilities, Basis Difference of Convertible Notes
Deferred tax liability on 5.375% Convertible Notes
Represents the deferred tax liability recognized for the original basis difference between the principal amount of the Convertible Notes and value allocated to the liability component, which resulted in a corresponding reduction to the valuation allowance recorded against deferred tax assets.
Deferred Tax Liabilities, Prepaid Expense
Prepaid expenses
Represents the amount as of the balance sheet date of the estimated future tax effects attributable to the difference between the tax basis of expenses funded in advance and the basis of a prepaid expense asset determined in accordance with generally accepted accounting principles.
Deferred Tax Liabilities, Unrealized Foreign Currency Translation Gains (Losses)
Deferred tax liability related to the unrealized foreign exchange gain
The amount of the deferred tax liability relating to foreign currency exchange gains (losses) of the reporting entity.
Represents the delayed draw term loan facility maturing on April 20, 2016.
Delayed Draw Facility
Delayed Draw Facility [Member]
Dermatology I P R D [Member]
Represents the acquired in-process research and development intangible asset related to the development of certain dermatology products.
Dermatology products
Represents the information pertaining to acquisition of the assets of the Dermik and Ortho Dermatologics.
Dermik and Ortho Dermatologics
Dermik and Ortho Dermatologics Assets [Member]
Dermik [Member]
Dermik
Represents information pertaining to Dermik, a dermatology unit of Sanofi.
Dermik Ortho Dermatologists Elidel Xerese Ora Pharma Pedinol University Medical Eyetech [Member]
Dermik, Ortho Dermatologists, Elidel/Xerese, OraPharma, Pedinol, University Medical and Eyetech
Information pertaining to Dermik, Ortho Dermatologists, Elidel/Xerese, OraPharma, Pedinol, University Medical and Eyetech.
Difference Between Estimated Fair Value and Purchase Price of Debt
Difference between the estimated fair value and the repurchase price of securities
Represents the difference between the estimated fair value of payments made and the purchase price of debt.
Difference Between Fair Value of Long Term Debt and Fair Value of Shares Issued for Conversion
Difference between estimated fair value of notes and fair value of common shares issued upon settlement
Represents the difference between the estimated fair value of notes and the fair value of common shares issued upon the conversion.
Difference Between Net Carrying Amount and Purchase Price
Difference between the net carrying amount and the purchase price
Represents the difference between the net carrying amount and the purchase price of debt.
Diltiazem Hydrochloride Capsules [Member]
Diltiazem hydrochloride capsules
Represents the information relating to matters concerning the entity pertaining to diltiazem hydrochloride capsules products.
Disposal Group Including Discontinued Operation Costs of Services Rendered
Cost of services
Represents the amount of costs of services rendered attributable to the disposal group, including a component of the entity (discontinued operation), during the reporting period.
Disposal Group Including Discontinued Operation Foreign Exchange Gain (Loss)
Foreign exchange gain (loss)
Represents the foreign exchange gain or loss attributable to the disposal group, including a component of the entity (discontinued operation), during the reporting period.
Disposal Group Including Discontinued Operation Net Income (Loss)
Net loss
Represents the amount of net income (loss) attributable to the disposal group, including a component of the entity (discontinued operation), during the reporting period.
Disposal Group Including Discontinued Operation Selling General and Administrative Expense
Amount of costs of selling, general and administrative expenses attributable to the disposal group, including a component of the entity (discontinued operation), during the reporting period.
Selling, general and administrative expenses
Document and Entity Information
Dosage Strength
Represents the dosage strength of a pharmaceutical product.
Dosage strength (in mg)
Dosage Strength Alternate
Alternate dosage strength (in mg)
Represents the dosage strength of a pharmaceutical product.
Effect on Retained Earnings (Accumulated Deficit) Due to Early Repayments of Convertible Debt
Difference between the estimated fair value and the purchase price of securities charged to accumulated deficit
Represents the difference between the fair value of payments made and the carrying amount of debt, charged to retained earnings or accumulated deficit.
Effexor X R [Member]
Effexor XR
Represents the information relating to matters concerning the entity pertaining to effexor XR products.
Elan and Elan Parties [Member]
Elan and Elan parties
Represents the allegation proceeding filed by the entity, Elan Pharma International Ltd. (Elan) and Fournier Laboratories Ireland Ltd. ("Elan parties").
Elidel [Member]
Elidel
Represents information pertaining to Elidel
Represents the products and services of both Elidel and Xerese.
Elidel and Xerese
Elidel Xerese [Member]
Emerging Markets [Member]
Emerging Markets
Represents the Emerging Markets segment of the entity. The segment consists of branded generic pharmaceutical products, as well as OTC products and agency/in-licensing arrangements with other research-based pharmaceutical companies (where the entity distributes and markets branded, patented products under long-term, renewable contracts). Products are sold primarily in Europe (Poland, Serbia, Hungary, Croatia and Russia), Latin America (Mexico, Brazil and exports out of Mexico to other Latin American markets), South East Asia and South Africa.
Employee Group [Axis]
The employee group prior to the merger.
Employee Group [Domain]
Represents the employee group prior to the merger.
ACCRUED LIABILITIES.
Equipment and Leasehold Improvements [Member]
Equipment and leasehold improvements
Represents the a) Tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services and b) Long lived, depreciable asset that is an addition or improvement to assets held under a lease arrangement.
Excess of Repurchase Price over Carrying Value Charged to Retained Earnings Accumulated Deficit
Excess of repurchase price over carrying value of securities repurchased, charged to accumulated deficit
Represents the excess of repurchase price over carrying value of securities repurchased pursuant to the entity's securities repurchase program, charged to retained earnings or accumulated deficit.
Exercise Price Range Five [Member]
Exercise price, range five
Represents the fifth slab of the exercise price ranges.
Exercise Price Range Four [Member]
Exercise price, range four
Represents the fourth slab of the exercise price ranges.
Exercise Price Range One [Member]
Exercise price, range one
Represents the first slab of the exercise price ranges.
Represents the sixth slab of the exercise price ranges.
Exercise Price Range Six [Member]
Exercise price, range six
Exercise price, range three
Represents the third slab of the exercise price ranges.
Exercise Price Range Three [Member]
Accrued Professional Fees, Current
Professional fees
Exercise Price Range Two [Member]
Exercise price, range two
Represents the second slab of the exercise price ranges.
Expenditure Recognized, Deferred Tax Liabilities
The amount of expenditure recognized to the extent of the deferred tax liabilities arriving from merger.
Expenditure recognized arriving from merger
Extinguishment of Debt [Text Block]
LOSS ON EXTINGUISHMENT OF DEBT
Schedule of amount of gain or loss on the extinguishment of debt.
Eyetech Inc [Member]
Eyetech Inc
Represents information pertaining to Eyetech Inc.
Ezogabine/retigabine
Represents the acquired in-process research and development intangible asset related to the development of ezogabine/retigabine.
Ezogabine Retigabine I P R D [Member]
Fair Value Measurement with Unobservable Inputs, Reconciliation Recurring Basis Asset and Liability Included in Other Comprehensive Income Reclassified to Net Income (Loss)
Total unrealized gains (losses) included in other comprehensive income, reclassification to net income (loss)
This element represents total gains or losses during the period, arising from assets and liabilities measured at fair value on a recurring basis using unobservable inputs (level 3), which are reclassified from other comprehensive income to net income (loss) during the reporting period.
UNITED STATES
U.S
Fair Value Measurement with Unobservable Inputs Reconciliation Recurring Basis Asset Liability Gain (Loss) Reclassified from Other Comprehensive Income
Total unrealized gains (losses) included in net income (loss), reclassification from other comprehensive income
This element represents total gains or losses during the period, arising from assets and liabilities measured at fair value on a recurring basis using unobservable inputs (level 3), which are reclassified from other comprehensive income during the reporting period.
This element represents an asset or liability measured at fair value using significant unobservable inputs (Level 3) which is required for reconciliation purposes of beginning and ending balances.
Balance, end of year
Balance, beginning of year
Fair Value Measurement with Unobservable Inputs, Reconciliation Recurring Basis, Asset, Liability Value
Fair Value Measurement with Unobservable Inputs, Reconciliation Recurring Basis Liability Foreign Currency Translation Gain (Loss) Included in Earnings
Foreign Exchange
This element represents the foreign currency translation gains or losses for the period arising from liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3), which are included in earnings or resulted in a change in net asset value.
False Claims Act
False Claim Act [Member]
Represents information relating to complaint filed under the False Claims Act concerning the entity.
Fenofibrate
Fenofibrate Tablets [Member]
Represents the information relating to matters concerning the entity pertaining to fenofibrate products.
Intangible assets
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Fipamezole
Represent the acquisition of U.S. and Canadian rights to develop, manufacture and commercialize fipamezole. The acquisition was accounted for as a purchase of IPR&D assets with no alternative future use.
Fipamezole [Member]
Fluorouracil Cream [Member]
Fluorouracil cream ("5-FU")
Represents the divestitures of fluorouracil cream (5-FU).
Fluorouracil Topical Cream [Member]
Represents the information relating to matters concerning the entity pertaining to fluorouracil topical cream, 0.5% products.
Fluorouracil topical cream, 0.5%
U.S. Federal, State and Local
Foreign Country State and Local [Member]
The designated tax department of state or local government of a foreign country entitled to levy and collect income taxes from the entity.
Foreign Currency Translation Gain (Loss) Unrealized
Unrealized foreign exchange gain
Represents the unrealized gains on translation of face amount of convertible notes to reporting currency for tax purposes.
G D N F [Member]
GDNF
Represents the entity's license and collaboration agreement with Amgen Inc. (Amgen) and MedGenesis Therapeutix Inc. (MedGenesis) pursuant to which the Company was granted a license to exploit GDNF in certain central nervous system (CNS) indications in certain countries and to develop and commercialize GDNF. The acquisition was accounted for as a purchase of IPR&D assets with no alternative future use.
Gain(Loss) on Auction Rate Securities
This item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of selling or holding auction rate securities.
Loss on auction rate securities
This item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of settlement of auction rate securities.
Gain(Loss) on Auction Rate Securities Settlement
Gain on auction rate securities settlement
Gain (Loss) on Auction Rate Security Settlement
Gain on auction rate security settlement
The value of gain or loss resulting from the settlement of auction rate security arbitration by the entity against a third party.
Represents the acquisition of Ganehill Pty Limited, an Australian company engaged in the marketing and distribution of skin care products under the Invisible Zinc brand.
Ganehill Pty Limited ("Ganehill")
Ganehill Pty Limited [Member]
Ganehill
Represents the information relating to general civil actions concerning the entity.
General civil actions
General Civil Actions [Member]
Gerot Lannach, Atlantis and Probiotica
Represents information pertaining to Gerot Lannach, Atlantis and Probiotica.
Gerot Lannach and Atlantis and Probiotica [Member]
Accrued Income Taxes, Current
Income taxes payable
Gerot Lannach
Gerot Lannach [Member]
Represents information pertaining to Gerot Lannach.
GlaxoSmithKline
Represents the information related to GlaxoSmithKline.
Glaxo Smith Kline [Member]
Represents the information relating to matters concerning the entity pertaining to Glumetza products.
Glumetza
Glumetza [Member]
Goodwill [Abstract]
Goodwill testing
Hamilton Brands [Member]
Hamilton Brands
Represents the acquisition of intellectual property, trademarks and inventory related to the Hamilton skin care brand in Australia. The acquisition was accounted for as a purchase of identifiable intangible assets.
I D P 111 and 5 F U [Member]
Divestitures of IDP-111 and 5-FU
Represents information pertaining to Divestitures of IDP-111 and 5-FU.
Impairment of Intangible Assets, Net of Gain (Loss) on Disposals [Text Block]
INTANGIBLE ASSET IMPAIRMENTS, NET OF GAIN ON DISPOSAL
This element represents the impairment of intangible assets, net of gain Loss on disposals.
LOSS ON IMPAIRMENT OF INVESTMENTS
IPR&D Termination Costs
Represents termination of product-development programs associated with exit from or disposal of business activities or restructurings pursuant to a plan.
In Process Research and Development Termination [Member]
Schedule reflecting information as tax authority, income tax expense benefit from continuing operations, unrecognized tax benefits.
Income Tax Authority, Income Tax Disclosure [Table]
Income Tax Expense (Benefit), Continuing Operations [Line Items]
Income tax Expense Benefit
Income Tax [Line Items]
INCOME TAXES
Accrued Employee Benefits, Current
Employee Costs
Income Tax Reconciliation Alternative Minimum and Other Taxes
Alternative minimum and other taxes
The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to alternative minimum and other taxes.
Income Tax Reconciliation Change in Operating Losses Valuation Allowance
Change in valuation allowance related to U.S. Operating losses
The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to change in valuation allowance related to operating losses.
Income Tax Reconciliation Foreign Currency Transaction, Gain
The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to foreign exchange gain for domestic tax purposes.
Canadian dollar foreign exchange (loss) gain for Canadian tax purposes
Accrued Liabilities, Current
Accrued liabilities and other current liabilities
Amount due shareholders of acquiree
Income Tax Reconciliation Foreign Withholding Tax
Withholding taxes on foreign income
Represents the portion of the difference between total income tax expense or benefit as reported in the income statement and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to foreign withholding tax.
Income Tax Reconciliation Loss of State and Local Net Operating Income (Losses)
Loss of U.S. state net operating losses
The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to loss on state net operating losses.
Income Tax Reconciliation Nondeductible Expense Legal Settlement Costs
Legal settlement costs
The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to differences in the deductibility of legal settlement costs in accordance with generally accepted accounting principles and enacted tax laws.
The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to differences in the deductibility of merger costs in accordance with generally accepted accounting principles and enacted tax laws.
Income Tax Reconciliation, Nondeductible Expense, Merger Costs
Merger costs
Income Tax Reconciliation, Uncertain Tax Positions
The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to uncertain tax positions.
Change in uncertain tax positions
Income Tax Reconciliation Unrecognized Tax Benefits
Unrecognized income tax benefit of losses
The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to unrecognized income tax benefit of losses.
Income Tax [Table]
Schedule of information relating to income taxes.
Increase (Decrease) in Retained Earnings
This element represents a reconciliation of a concept from the beginning of a period to the end of a period.
Increase (Decrease) in Retained Earnings [Roll Forward]
Transfer to restricted cash
Increase in Restricted Cash
The value of cash outflow of funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.
Incremental Term Loan B [Member]
Incremental Term Loan B
Represents the incremental term B loans obtained under the Senior Secured Credit Facilities of the reporting entity.
Inova and Dermik [Member]
Inova and Dermik operations
Represents information pertaining to iNova and Dermik.
Inova Dermik and Afexa [Member]
Represents information pertaining to iNova, Dermik and Afexa.
iNova, Dermik and Afexa
Inova Pharmaceuticals [Member]
Represents information pertaining to iNova Pharmaceuticals.
iNova
INSURANCE RECOVERIES RECEIVABLE
Insurance Recoveries Receivable [Text Block]
INSURANCE RECOVERIES RECEIVABLE
This element encapsulates disclosures pertaining to insurance recoveries receivable.
INTANGIBLE ASSET IMPAIRMENTS, NET OF GAIN ON DISPOSAL
Intangible Assets Disclosure, Excluding Impairments [Text Block]
INTANGIBLE ASSETS
This element encapsulates disclosures pertaining to intangible assets, excluding impairments on them.
INTANGIBLE ASSETS.
Internal and External Costs Incurred
Internal and external costs incurred
Represents the internal and external costs incurred.
Istradefylline
Represents the acquisition of U.S. and Canadian rights to develop and commercialize products containing istradefylline. The acquisition was accounted for as a purchase of identifiable intangible assets.
Istradefylline [Member]
Accrued Royalties, Current
Royalties
J and J, North America, Q L T, University Medical, Atlantis Pharma, Gerot Lannach and Probiotica [Member]
J&J North America, QLT, University Medical, Atlantis Pharma, Gerot Lannach and Probiotica
Represents information pertaining to J and J North America, QLT, University Medical, Atlantis Pharma, Gerot Lannach and Probiotica.
Johnson and Johnson Consumer Companies Inc [Member]
Johnson & Johnson Consumer Companies Inc
Represents information pertaining to Johnson and Johnson Consumer Companies Inc.
Lacricert [Member]
Lacrisert
Represents information pertaining to Lacrisert.
Represents the information pertaining to Lamictal ODT.
Lamictal ODT
Lamictal O D T [Member]
Lamotrigine Tablets [Member]
Lamotrigine Tablets
Represents the information relating to matters concerning the entity pertaining to lamotrigine tablets products.
Represents the information relating to legacy valeant litigation concerning the entity.
Legacy Valeant Litigation
Legacy Valeant Litigation [Member]
Limitations on use of operating losses resulting from merger
Represents the details pertaining to limitation on use of operating losses resulting from merger.
Limitations on Use of Operating Losses Resulting from Merger [Member]
Line of Credit Facility, Additional Borrowing Capacity
Additional term loan facilities for term loan facility or revolving credit facility
Represents additional borrowing capacity available under the credit facility.
Line of Credit Facility, Annual Amortization Percentage after Initial Term
Annual amortization of credit facilities commencing March 31, 2013 (as a percent)
Represents the annual rate amortization of original principal amount after the initial term.
Accumulated Defined Benefit Plans Adjustment [Member]
Pension Adjustment
Line of Credit Facility, Annual Amortization Percentage after Second Term
Annual amortization of credit facilities commencing March 31, 2014 (as a percent)
Represents the annual rate amortization of original principal amount after the second term.
Line of Credit Facility, Annual Excess Cash Flow Payable as Mandatory Prepayments Percentage of Step Down Based on Achievement of Specific Leverage Ratio
Percentage of annual excess cash flow with any excess amount after prepayment of the loans with a step down based on achievement of a specified leverage ratio
Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans with a step down based on achievement of a specified leverage ratio.
Line of Credit Facility, Average Aggregate Daily Maximum Amount Available Commitment Fee, Percentage
Commitment fee, average aggregate daily maximum amount available to be drawn, percentage
The fee, expressed as a percentage of the line of credit facility, in respect of the average aggregate daily maximum amount available to be drawn under the credit facility.
Line of Credit Facility, Capital Expenditure Permitted
Aggregate amount of capital expenditures permitted to be made
Represents the aggregate amount of capital expenditures permitted to be made during any fiscal year under the term of credit agreement.
Represents the maximum amount of unused capital expenditure capacity which can be carried forward from immediately preceding fiscal year under the terms of the credit agreement.
Line of Credit Facility, Carryforward of Unused Capital Expenditure Amount
Amount of capital expenditure that can be carried forward
Line of Credit Facility, Carryforward of Unused Capital Expenditure Period
Period of carryforward of capital expenditure
Represents the period for which unused capital expenditure can be carried forward under the terms of the credit agreement.
Line of Credit Facility Collateral Percentage of Entity and Domestic Subsidiaries Capital Stock
Percentage of capital stock of the entity and domestic subsidiaries pledged as collateral for borrowings
Represents the percentage of the capital stock of the entity and domestic subsidiaries pledged as collateral for the credit agreement.
Line of Credit Facility Collateral Percentage of Entity and Other Subsidiaries Capital Stock
Percentage of capital stock of the entity and each other subsidiary of the company (other than Valeant's subsidiaries) that is owned by a guarantor
Represents the percentage of the capital stock of the entity and each other subsidiary of the company (other than Valeant's subsidiaries), that is owned by a guarantor, pledged as collateral for the credit agreement.
Percentage of capital stock of foreign subsidiaries pledged as collateral for borrowings
Represents the percentage of the capital stock of the entity's foreign subsidiaries pledged as collateral for the credit agreement.
Line of Credit Facility Collateral Percentage of Foreign Subsidiaries Capital Stock
Net Unrealized Holding Gain (Loss) on Securities
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Line of Credit Facility, Delayed Draw
Delayed draw included in Term loan facility
Amount of delayed draw available under the line of credit facility.
Line of Credit Facility Increase in Maximum Borrowing Capacity
Increase in amount of commitments under credit facility
Represents the amount of increase in maximum borrowing capacity under the credit facility.
Initial draw included in Term loan facility
Line of Credit Facility, Initial Draw
Initial draw
Amount of initial draw available under the line of credit facility.
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Other Comprehensive (Loss) Income
Line of Credit Facility Maximum Borrowing Amount of Increase
Maximum borrowing capacity increase
Represents the increase in the amount of the maximum borrowing capacity under the credit facility.
Line of Credit Facility, Maximum Interest Coverage Ratio
Represents the numerator for the maximum interest coverage ratio.
Interest coverage ratio, maximum
Represents the numerator for the maximum secured leverage ratio through the first year after the balance sheet date.
Line of Credit Facility Maximum Secured Leverage Ratio Through One Year
Secured leverage ratio for last day of each quarter including the fiscal quarter ending March 31, 2012, maximum
Line of Credit Facility, Obligations Equivalent Percentage of Total Assets of Entity or Subsidiaries
Percentage of consolidated total assets of the company or its subsidiaries
Represents the percentage equivalent of total assets of the entity or its subsidiaries for obligations under credit facilities, as well as certain hedging arrangements and cash management arrangements entered into with lenders under the credit facilities.
Line of Credit Facility, Obligations Equivalent Percentage of Total Revenues of Entity and Subsidiaries
Percentage of the total revenues of the company and its subsidiaries
Represents the percentage equivalent of total revenues of the entity and its subsidiaries for obligations under credit facilities, as well as certain hedging arrangements and cash management arrangements entered into with lenders under the credit facilities.
Line of Credit Facility, Percentage Annual Amortization for First and Second Year
Annual amortization of credit facilities for first and second year (as a percent)
Represents the annually amortization of original principal amount for first and second year.
Line of Credit Facility, Percentage Annual Amortization for Third and Fourth Year
Annual amortization of credit facilities for third and fourth year (as a percent)
Represents the annually amortization of original principal amount for third and fourth year.
Line of Credit Facility, Percentage of Annual Amortization for Last Year
Annual amortization of credit facilities for last year (as a percent)
Represents the annually amortization of original principal amount for last year.
Line of Credit Facility, Percentage of Consolidated Excess Cash Flow Payable as Mandatory Prepayments
Percentage of annual excess cash flow
Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.
Line of Credit Facility, Percentage of Net Cash Proceeds from Asset Sales Outside Ordinary Course of Business Payable as Mandatory Prepayments
Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments
Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.
Line of Credit Facility, Percentage of Net Cash Proceeds from Issuance of Equity Securities Payable as Mandatory Prepayments
Percentage of cash proceeds from issuance of equity securities payable as mandatory prepayments
Represents the percentage of net cash proceeds from the issuance of equity securities subject to decrease based on leverage ratios payable as mandatory prepayments.
Line of Credit Facility, Percentage of Net Cash Proceeds of Insurance and Condemnation Proceeds from Property or Asset Losses Payable as Mandatory Prepayments
Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses
Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.
Percentage of cash proceeds from incurrence of debt
Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.
Line of Credit Facility, Percentage of Net Proceeds from Incurrence of Debt Payable as Mandatory Pre-payments
Line of Credit Facility, Percentage of Quarterly Amortization for First and Second Year
Quarterly amortization of credit facilities for first and second year (as a percent)
Represents the amortization in quarterly installments of original principal amount for first and second year.
Represents the amortization in quarterly installments of original principal amount for third and fourth year.
Line of Credit Facility, Percentage of Quarterly Amortization for Third and Fourth Year
Quarterly amortization of credit facilities for third and fourth year (as a percent)
Line of Credit Facility, Proceeds from Issuance of Equity Securities Payable as Mandatory Prepayments Percentage of Step Down Based on Achievement of Specific Leverage Ratio
Percentage of step down on achievement of a specified leverage ratio
Represents the percentage of net cash proceeds received from certain issuances of equity interests with a step down based on achievement of a specified leverage ratio.
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Less accumulated depreciation
Line of Credit Facility Quarterly Amortization Percentage Annual Rate
Quarterly amortization of credit facilities, annual rate (as a percent)
Represents the annual rate for the amortization in quarterly installments of original principal amount.
Line of Credit Facility, Quarterly Amortization Percentage, Initial Rate
Quarterly amortization of credit facilities, initial rate (as a percent)
Represents the initial rate for the amortization in quarterly installments of original principal amount.
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive loss
Balance at the beginning of the period
Balance at the end of the period
Line of Credit Facility, Remaining Unamortized Balance after Fourth Year
Remaining balance after fourth year (as a percent)
Represents remaining unamortized balance under line of credit facility after fourth year of issuance.
Lodalis
Represents the acquisition of the Canadian rights to Lodalis. The acquisition was accounted for as a purchase of in-process research and development assets with no alternative future use.
Lodalis [Member]
Carrying amount of notes prior to conversion
Represents the carrying amount of notes prior to conversion.
Long Term Debt Carrying Amount Prior to Conversion
Long Term Debt Fair Value Prior to Conversion
Fair value of notes prior to conversion
Represents the fair value of notes prior to conversion.
Accumulated Translation Adjustment [Member]
Foreign Currency Translation Adjustment
Long Term Debt Redemption Price as Percentage of Principal Amount Prior to October 2015
Redemption price as a percentage of the principal amount, if Senior Notes are redeemed prior to October 15, 2015
Represents the redemption price as a percentage of the principal amount, if the entity redeems some or all of the debt instruments prior to October 15, 2015.
Long Term Debt Redemption with Net Proceeds from Equity Offerings as Percentage of Principal Amount
Redemption price as a percentage of principal amount using the net proceeds of equity offerings
Represents the percentage of the aggregate principal amount of debt instruments that may be redeemed using the net proceeds of certain equity offerings prior to October 15, 2015.
LONG-TERM INVESTMENTS
Long Term Investments, Excluding Impairments [Text Block]
LONG-TERM INVESTMENTS
This element encapsulates disclosures pertaining to the long-term investments of the entity.
Loss Contingency, Duration for Motions to Dismiss after Complaint is Unsealed
Duration for motion to dismiss, after the complaint is unsealed
Represents the number of days due for motions to dismiss after the complaint is unsealed in respect of each defendant.
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life
Estimated weighted-average useful life
Loss Contingency Number of Actions Consolidated in First Filed Case
Number of actions consolidated into the first-filed case
Represents the number of actions that have been consolidated into first-filed case.
Number of motions responded for partial summary judgment
Loss Contingency, Number of Motions Responded for Partial Summary Judgment
Represents the number of motions for partial summary judgment responded by the entity.
Loss Contingency Number of Other Companies Named as Defendants
Number of other companies named as defendants
Represents the number of companies named as defendants in a lawsuit.
Loss Contingency, Number of Patents Remain in Litigation
Number of the patents that remain in the litigation
Represents the number of patents of the entity that remain in the litigation.
Loss Contingency Number of Product Liability Complaints Dismissed
Number of complaints dismissed
Represents the number of complaints served to the entity, subsequently dismissed by the court.
Loss Contingency, Number of Product Liability Complaints Served
Number of complaints served
Represents the number of complaints served to the entity.
Acquired Finite-lived Intangible Asset, Amount
Identifiable intangible assets
Loss Contingency Obligation Term
Represents the term of obligations under the agreement entered by the entity.
Obligation term
Loss Contingency Penalty Amount
Civil Penalty
Represents the amount of penalty charged against the entity.
Loss Contingency Period of Stay on FDA Approval
Period of stay on approval
Represents the period of stay on FDA approval.
Period of stay under The Hatch-Waxman Act
Loss Contingency, Settlement Agreement Maximum Amount of Consideration
Represents the maximum amount of consideration paid by the entity under settlement agreement which resolved the legal matter.
Maximum amount of consideration paid under settlement agreement
Loss on Early Extinguishment of Debt
Loss on extinguishment of debt
Amount represents the difference between the fair value of the payments made and the carrying amount of the debt at the time of its early extinguishment.
LOSS ON EXTINGUISHMENT OF DEBT
Loss on Impairment of Investments [Text Block]
LOSS ON IMPAIRMENT OF INVESTMENTS
This element represents the loss on impairment of investments.
Additional Paid in Capital, Common Stock
Additional paid-in capital
Manufacturing agreements
Manufacturing Agreements [Member]
Represents the intangible assets relating to manufacturing agreements.
Manufacturing Facility at Carolina [Member]
Manufacturing facility at Carolina
Represents the manufacturing facility at carolina, held for sale.
Manufacturing Operations [Member]
Manufacturing Operations
Details pertaining to manufacturing operations of the entity.
Marketable Securities Portfolio [Member]
Marketable securities portfolio
Represents the portfolio of marketable securities, when it serves as a benchmark in a concentration of risk calculation, representing the sum of all marketable securities as of the balance sheet date.
Maximum Term of Original Maturity of Marketable Securities
Represents the maximum term of original maturity of marketable securities.
Maximum term of original maturity of marketable securities
Maximum Term of Original Maturity to Classify Instruments as Cash and Cash Equivalents
Maximum term of original maturity to classify instruments as cash and cash equivalents
Represents the maximum original term of maturity for an instrument to be classified as cash or cash equivalent.
Mc Kesson Corporation [Member]
McKesson Corporation
Represents the major customer of the entity, McKesson Corporation.
Meda Pharma GmbH & Co. KG (Meda Pharma)
Represents the information related to Meda Pharma GmbH & Co. KG.
Meda Pharma Gmb H and Company K G [Member]
Medicis Pharmaceutical Corporation [Member]
Represents information pertaining to Medicis Pharmaceutical Corporation.
Medicis
Additional Paid-In Capital
Additional Paid-in Capital [Member]
Minimum period to classify uncertain tax position liabilities as long term liabilities
Represents the minimum period to classify uncertain tax position liabilities as long term liabilities.
Minimum Period to Classify Uncertain Tax Position, Liabilities as Long Term Liabilities
Minority Interest Ownership by Noncontrolling Owners Number of Shares
Noncontrolling interest, number of shares
The equity interest, in shares, of noncontrolling shareholders, partners or other equity holders in consolidated entity.
More Likely than Not Probability Threshold, Minimum
Indefinite-lived intangible impairment testing, the "more likely than not" probability threshold minimum (as a percent)
The "more likely than not" probability threshold must be greater than this percentage.
Represents the information relating to matters concerning the entity pertaining to Mylan Pharmaceuticals ULC.
Mylan
Mylan Pharmaceuticals U L C [Member]
Name of Operations [Domain]
Name and description of type of operations carried out by the entity.
Natur Produkt International J S C [Member]
Natur Produkt
Represents the information pertaining to the entity Natur Produkt International, JSC.
Net Assets Liabilities of Disposal Group Including Discontinued Operation Current
Net assets and liabilities of disposal group, Current
Represents the value (measured at the lower of net carrying value or fair value less cost of disposal) of net current assets and liabilities (assets and liabilities with expected useful life shorter than one year or one operating cycle, whichever is longer) of a disposal group, including a component of the entity (discontinued operation), to be sold or that has subsequently been disposed of through sale, as of the financial statement date.
New Securities Repurchase Program [Member]
New Securities Repurchase Program
Represents information pertaining to the New Securities Repurchase Program of the entity.
Non Cash Cost Alliance Revenue
Non-cash cost of alliance revenue
Non-cash costs incurred and directly related to generating alliance revenue.
Long-term debt related to acquisition of business
Noncash Acquisition, Debt Assumed
The portion of the amount of debt that an entity acquires not resulting in cash payments in the period.
Represents the information pertaining to the non-prosecution agreement entered by the entity with the U.S. Attorney's office (USAO).
Non-prosecution agreement
Non-prosecution Agreement [Member]
Number of Agreements for which Several and Individual Class Action in Multiple Jurisdictions Commenced Jointly
Number of agreements for which several and individual class actions in multiple jurisdictions commenced jointly
Represents the number of agreements for which several and individual class actions in multiple jurisdictions commenced jointly.
Number of Auction Rate Securities
Represents the number of auction rate securities in which entity has invested during the reporting period.
Number of auction rate securities
Number of Countries of Operation
Number of countries of operation
Represents the number of countries where the operations are undertaken by the entity.
Number of Directors of Entity Against Whom Purported Class Action Complaint is Filed
Number of directors against whom class action complaint is filed by stockholder
Represents the number of directors against whom class action complaint is filed by stockholder.
Number of Entities Against which Suits are Filed
Number of companies against which suits are filed
Represents the number of companies against which suits are filed.
Number of Generic Drug Entities from which Notice of Patent Applications are Received
Number of generic drug companies from which notices of patent applications are received
Represents the number of generic drug companies from which notices of patent applications are received.
Number of Largest Wholesale Customers
Number of largest wholesale customers
Represents the number of largest wholesale customers.
Number of New Countries in which Entity Operates
Number of new countries in which entity operates
The number of new countries in which the entity operates as of the balance sheet date.
Number of patents listed in the FDA's Orange Book
Number of Patents Listed in the FDA Orange Book
Represents the number of patents listed in the FDA's Orange Book.
Number of Products in Product Portfolio
Number of products in product portfolio
Represents the number of products in the product portfolio.
Number of Therapeutic Areas
Number of therapeutic areas in which broad product portfolio is offered
Represents the number therapeutic areas in which broad product portfolio is offered.